The use of mid-regional proadrenomedullin to identify disease severity and treatment response to sepsis - a secondary analysis of a large randomised controlled trial

The use of mid-regional proadrenomedullin to identify disease severity and treatment response to sepsis - a secondary analysis of a large randomised controlled trial

Abstract Background This study assessed the ability of mid-regional proadrenomedullin (MR-proADM) in comparison to conventional biomarkers (procalcitonin (PCT), lactate, C-reactive protein) and clinical scores to identify disease severity in patients with sepsis. Methods This is a secondary analysis...

Full description

Bibliographic Details
Main Authors: Gunnar Elke, Frank Bloos, Darius Cameron Wilson, Frank Martin Brunkhorst, Josef Briegel, Konrad Reinhart, Markus Loeffler, Stefan Kluge, Axel Nierhaus, Ulrich Jaschinski, Onnen Moerer, Andreas Weyland, Patrick Meybohm, the SepNet Critical Care Trials Group
Format: Article
Language:English
Published: BMC 2018-03-01
Series:Critical Care
Subjects:
MR-proADM
Biomarkers
Sepsis
Mortality
SOFA
Septic shock
Online Access:http://link.springer.com/article/10.1186/s13054-018-2001-5

Internet

http://link.springer.com/article/10.1186/s13054-018-2001-5

Similar Items